Evaluating staging systems for skin cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on cutaneous squamous cell carcinoma (CSCC), the second most common form of skin cancer. Researchers will assess existing CSCC cases from two dermatology centers in the UK to evaluate how accurately current staging systems predict the risk of poor outcomes, such as metastasis and mortality. The goal is to validate the predictive power of histological staging classifications and potentially identify improved prediction tools for better patient management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Over 18 years old with diagnosis of CSCC

Exclusion Criteria:

* Patients who decline for their data to be used for research purposes

Where it's running

• Whipps Cross University Hospital
  London, United Kingdom Recruiting
• Dr Emilia Peleva
  London, United Kingdom Active not recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cemiplimab with Quad Shot Radiation for Head and Neck Cutaneous Squamous Cell Carcinoma

  This study tests whether giving cemiplimab together with a short course of Quad Shot radiation can be safely delivered in several rounds to elderly or frail patients with head and neck skin cancer.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · St Louis, Missouri · NCT07869823

• IDP-001 in advanced or metastatic solid tumors (including head and neck and skin cancers)

  A first- and second-phase study will test IDP-001 in people with advanced or metastatic solid tumors to see if it is safe and tolerable and to look for signs of activity.

  Recruiting at 6 sites Phase 1/2 InduPro, Inc. · Los Angeles, California and 5 other locations · NCT07602842

• Cosibelimab for tough CSCC in kidney transplant recipients or blood cancers

  This trial tests cosibelimab in people with advanced cutaneous squamous cell carcinoma who have a kidney transplant or certain blood cancers to see if it is safe and helpful for them.

  Recruiting at 2 sites Phase 4 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07426484

• 3D ultrasound of removed cutaneous squamous cell carcinoma specimens

  For adults having surgery to remove cutaneous squamous cell carcinoma, this will try ex vivo 3D ultrasound of the removed specimen to see if it can accurately measure the deep margin compared with standard pathology.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT07402616

• Lifileucel (TIL) plus chemotherapy and IL-2 for advanced cutaneous squamous cell and Merkel cell carcinoma

  This trial will try lifileucel (tumor-infiltrating lymphocytes) combined with lymphodepleting chemotherapy and interleukin-2 in adults with unresectable or metastatic cutaneous squamous cell carcinoma or Merkel cell carcinoma who have previously received immunotherapy.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07288073

• Using blood tests to monitor skin cancer treatment

  This study is testing whether blood tests can help track how well treatment is working for people with skin cancer called cutaneous squamous cell carcinoma.

  Recruiting Massachusetts Eye and Ear Infirmary · Boston, Massachusetts · NCT06875609

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.